Novo NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with broad portfolios spanning major therapeutic areas. Novo is widely recognized for its leadership in diabetes and obesity, with its semaglutide franchise marketed under the Ozempic and Rybelsus brands for type II diabetes (T2D) and Wegovy for chronic weight management. The company is also expanding its obesity offering with oral formulations, seeking to broaden its reach in the fast-growing weight-loss market. Pfizer, meanwhile, has traditionally maintained significant strength across oncology, vaccines, inflammation and immunology, rare diseases and other therapeutic areas.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.